Lupus News

Belimumab treatment and standard therapy caused greater kidney outcomes among East Asian patients with lupus nephritis compared with standard therapy alone.

Sufficient disease control prior to conception can reduce the risk for pregnancy complications in patients with rheumatic conditions, according to a press release announcing data published in Rheumatic Disease Clinics of North America.

Ustekinumab failed to demonstrate superiority to placebo among patients with active systemic lupus erythematosus, according to phase-3 data published in Annals of the Rheumatic Diseases.

Although they exhibit a greater risk for severe immune-related adverse effects, patients with preexisting autoimmune disease receiving immune checkpoint inhibitors for melanoma had better 2-year survival than controls, according to data.

Leflunomide is non-inferior to azathioprine in terms of safety and efficacy for lupus nephritis maintenance therapy, according to data published in the Annals of the Rheumatic Diseases.

Patients with systemic lupus erythematosus who report a high quality of care do not necessarily report meaningful clinical differences in quality of life, according to data published in Arthritis Care & Research.

Recent data has revealed a growing divide between rheumatologists and nephrologists in their therapeutic choices for patients with lupus nephritis, according to researchers from Spherix Global Insights.

Exposure to fine particulate matter — specifically particles 2.5 µm or less in diameter, or PM2.5 — in the air signals a higher risk for systemic autoimmune rheumatic diseases, according to data published in Arthritis Research & Therapy.

Addressing the racial disparities that continue to plague health care requires “continuous” work, as well as holding certain providers’ “feet to the fire,” said a presenter at the 2022 Association of Women in Rheumatology annual conference.

The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.